<DOC>
	<DOCNO>NCT00409305</DOCNO>
	<brief_summary>The purpose study examine effect betahistine body weight obese subject .</brief_summary>
	<brief_title>The Effect Betahistine Body Weight Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Betahistine</mesh_term>
	<criteria>Signed write informed consent ; Male female subject 18 65 year age ; Is obese BMI great equal 30 kg/m2 less equal 40 kg/m2 ; Has obese least 1 year prior screening ; If female , nonlactating , negative urine pregnancy test result , plan become pregnant study , childbearing potential ( hysterectomy tubal ligation least 6 month prior randomization postmenopausal 1 year ) ; childbearing potential ( include perimenopausal woman menstrual period within 1 year ) must practice willing continue practice appropriate birth control ( implant , injectables , oral contraceptive , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner ) entire study duration . Has obesity know endocrine origin ( e.g. , Cushing 's disease , Addison 's disease , hypothalamic tumor ) ; Has medical history ( e.g. , morbid childhood obesity ) and/or physical characteristic ( e.g. , polydactyly ) suggestive genetic obesity ( e.g. , ob/ob genotype ) syndromatic obesity ( e.g. , PraderWilli syndrome , Bardet Biedl syndrome ) ; Previous surgical procedure weight loss ; Has liposuction within 1 year screen plan liposuction study ; History bulimia evidence laxative abuse ; Has body weight loss &gt; 4 kg 90 day prior screen ; Has take drug capable influence body weight 30 day prior screen ; Has recently start plan start smoke cessation program ; Has major change daily physical activity ( e.g. , initiation exercise program ) start weight loss program within 90 day prior screen ; Is unwilling unable participate dietary program part study ; Is &lt; 80 % compliant study medication singleblind placebo runin period ; Has clinically significant history presence follow condition : Active past history cardiovascular cerebrovascular disease include unstable angina , myocardial infarction , transient ischemic attacks/stroke , clinically significant arrhythmia , congestive heart failure , cardiac valve abnormality ; Liver disease ( irrespective transaminase concentration ) ; Pheochromocytoma ; Porphyria ; Type 1 diabetes mellitus ; Type 2 diabetes mellitus treatment metformin monotherapy and/or diet HbA1c le equal 8 % ; Severe type 2 diabetes history ketoacidosis diabetic ulcer , presence retinopathy , neuropathy , nephropathy ; Renal insufficiency define serum creatinine great equal 1.5 mg/dL ( 133 µmol/L ) screening ; Malignant disease within 5 year screen ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 x ULN ; Thyroidstimulating hormone ( TSH ) outside normal range ; Plans surgery ( elective otherwise ) course study ; Has uncontrolled hypertension ( sit blood pressure &gt; 160/95 mmHg screen randomization ) , uncontrolled hyperlipidemia ( triglycerides [ TG ] great equal 400 mg/dL lowdensity lipoprotein cholesterol [ LDLC ] &gt; 160 mg/dL ) , uncontrolled diabetes ( HbA1c &gt; 8 % ) ; History asthma ; History peptic ulcer ; History HIV ; History undiagnosed allergy , severe allergy , drug allergy , include history anaphylaxis , angioedema , bronchospasm , urticaria ; Has clinical laboratory test value ( chemistry , hematology , urinalysis ) judge clinically significant investigator ; Has physical examination electrocardiogram ( ECG ) significant abnormality , judge investigator ; Currently abuse drug alcohol history abuse investigator 's opinion could cause subject noncompliant study procedure ; Has hypersensitivity betahistine ; Has psychiatric neurological disorder require chronic medication ( e.g. , antidepressant ) , subject unlikely major depressive episode ( score lees equal 8 ) The Harvard Department Psychiatry National Depression Screening Day Scale ( THE HANDS ) ( See Appendix E ) ; Chronic need use antihistamine ; Has stable treatment regimen follow medication minimum 90 day prior screen : Hormone replacement therapy ; Oral contraceptive ; Antihypertensive agent ; Metformin ; Lipidlowering agent ; Thyroid replacement therapy ; Has treat past 60 day , currently treat , expect require undergo treatment follow excluded medication ; All prescription overthecounter agent take purpose weight reduction , include ( limit ) follow anti obesity agent : Prescription drug orlistat , sibutramine , phentermine ; Overthecounter antiobesity agent ( e.g. , herbal supplement alternative remedy Cortislim , Dexatrim , Acutrim ) ; Psychotropic/neurological agent include follow : Antipsychotic agent ( e.g. , olanzapine , clozapine , risperidol , lithium , etc. ) . Antiepileptic agent ( e.g. , Topamax® , Zonegran® , valproate , carbamazepine ) ; Antidepressant agent include follow : monoamine oxidase inhibitor , bupropion ( Wellbutrin® , Zyban® ) , tricyclic antidepressant , tetracyclic antidepressant ; selective serotonin reuptake inhibitor ( e.g. , Prozac® , Paxil® , Zoloft® , etc . ) ; Systemic steroid administer oral , intravenous , intramuscular route ; Drugs directly affect gastrointestinal motility ( e.g. , Reglan® Propulsid® , chronic [ take 10 day within 6month period ] macrolide antibiotic erythromycin new derivative ) ; Calcitonin ( e.g. , Miacalcin® ) ; Insulin ; Exenatide ( Byetta ) ; Sulfonylureas ( e.g. , Diamicron , Amaryl , Glucotrol , Micronase ) ; Meglitinides ( e.g. , Starlix , Prandin ) Has receive investigational drug within 90 day screen ; Receipt investigational treatment ( drug device ) within 90 day prior screen ; Is immediate family member personnel directly affiliate study investigative site , personally directly affiliate study investigative site ; Is employ OBEcure Ltd .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>